NCT03558191View on ClinicalTrials.gov

SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

PHASE2CompletedINTERVENTIONAL

Enrollment

156

Participants

Timeline

Start Date

August 14, 2018

Primary Completion Date

December 30, 2021

Study Completion Date

December 30, 2021

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG

SHR-1210

A humanized monoclonal immunoglobulin PD-1 antibody

Trial Locations (1)

510060

Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03558191 - SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy. | Biotech Hunter | Biotech Hunter